These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 26795874)

  • 81. Interactions between cognitive and sensory load while planning and controlling complex gait adaptations in Parkinson's disease.
    Pieruccini-Faria F; Ehgoetz Martens KA; Silveira CR; Jones JA; Almeida QJ
    BMC Neurol; 2014 Dec; 14():250. PubMed ID: 25528474
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Erratum.
    Mult Scler; 2016 Oct; 22(12):NP9-NP11. PubMed ID: 26041800
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
    Brightling CE; Chanez P; Leigh R; O'Byrne PM; Korn S; She D; May RD; Streicher K; Ranade K; Piper E
    Lancet Respir Med; 2015 Sep; 3(9):692-701. PubMed ID: 26231288
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial.
    Judson I; Morden JP; Kilburn L; Leahy M; Benson C; Bhadri V; Campbell-Hewson Q; Cubedo R; Dangoor A; Fox L; Hennig I; Jarman K; Joubert W; Kernaghan S; López Pousa A; McNeil C; Seddon B; Snowdon C; Tattersall M; Toms C; Martinez Trufero J; Bliss JM
    Lancet Oncol; 2019 Jul; 20(7):1023-1034. PubMed ID: 31160249
    [TBL] [Abstract][Full Text] [Related]  

  • 85. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
    Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
    Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Effect of monthly high-dose vitamin D supplementation on falls and non-vertebral fractures: secondary and post-hoc outcomes from the randomised, double-blind, placebo-controlled ViDA trial.
    Khaw KT; Stewart AW; Waayer D; Lawes CMM; Toop L; Camargo CA; Scragg R
    Lancet Diabetes Endocrinol; 2017 Jun; 5(6):438-447. PubMed ID: 28461159
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
    Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R
    Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial.
    Tardif JC; Bouabdallaoui N; L'Allier PL; Gaudet D; Shah B; Pillinger MH; Lopez-Sendon J; da Luz P; Verret L; Audet S; Dupuis J; Denault A; Pelletier M; Tessier PA; Samson S; Fortin D; Tardif JD; Busseuil D; Goulet E; Lacoste C; Dubois A; Joshi AY; Waters DD; Hsue P; Lepor NE; Lesage F; Sainturet N; Roy-Clavel E; Bassevitch Z; Orfanos A; Stamatescu G; Grégoire JC; Busque L; Lavallée C; Hétu PO; Paquette JS; Deftereos SG; Levesque S; Cossette M; Nozza A; Chabot-Blanchet M; Dubé MP; Guertin MC; Boivin G;
    Lancet Respir Med; 2021 Aug; 9(8):924-932. PubMed ID: 34051877
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial.
    Dinh A; Ropers J; Duran C; Davido B; Deconinck L; Matt M; Senard O; Lagrange A; Makhloufi S; Mellon G; de Lastours V; Bouchand F; Mathieu E; Kahn JE; Rouveix E; Grenet J; Dumoulin J; Chinet T; Pépin M; Delcey V; Diamantis S; Benhamou D; Vitrat V; Dombret MC; Renaud B; Perronne C; Claessens YE; Labarère J; Bedos JP; Aegerter P; Crémieux AC;
    Lancet; 2021 Mar; 397(10280):1195-1203. PubMed ID: 33773631
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Transcranial direct current stimulation (tDCS) in addition to walking training on walking, mobility, and reduction of falls in Parkinson's disease: study protocol for a randomized clinical trial.
    Nascimento LR; Nakamura-Palacios EM; Boening A; Cordeiro BNL; Cabral DL; Swarowsky A; Arêas GPT; Paiva WS; da Silva Arêas FZ
    Trials; 2021 Sep; 22(1):647. PubMed ID: 34548110
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial.
    Zakrzewska JM; Palmer J; Morisset V; Giblin GM; Obermann M; Ettlin DA; Cruccu G; Bendtsen L; Estacion M; Derjean D; Waxman SG; Layton G; Gunn K; Tate S;
    Lancet Neurol; 2017 Apr; 16(4):291-300. PubMed ID: 28216232
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Donepezil for gait and falls in mild cognitive impairment: a randomized controlled trial.
    Montero-Odasso M; Speechley M; Chertkow H; Sarquis-Adamson Y; Wells J; Borrie M; Vanderhaeghe L; Zou GY; Fraser S; Bherer L; Muir-Hunter SW
    Eur J Neurol; 2019 Apr; 26(4):651-659. PubMed ID: 30565793
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial.
    Trenkwalder C; Chaudhuri KR; Martinez-Martin P; Rascol O; Ehret R; Vališ M; Sátori M; Krygowska-Wajs A; Marti MJ; Reimer K; Oksche A; Lomax M; DeCesare J; Hopp M;
    Lancet Neurol; 2015 Dec; 14(12):1161-70. PubMed ID: 26494524
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Impact of depression on gait variability in Parkinson's disease.
    Dragašević-Mišković NT; Bobić V; Kostić M; Stanković I; Radovanović S; Dimitrijević K; Svetel M; Petrović I; Đurić-Jovičić M
    Clin Neurol Neurosurg; 2021 Jan; 200():106324. PubMed ID: 33129594
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Safety and efficacy of co-careldopa as an add-on therapy to occupational and physical therapy in patients after stroke (DARS): a randomised, double-blind, placebo-controlled trial.
    Ford GA; Bhakta BB; Cozens A; Hartley S; Holloway I; Meads D; Pearn J; Ruddock S; Sackley CM; Saloniki EC; Santorelli G; Walker MF; Farrin AJ
    Lancet Neurol; 2019 Jun; 18(6):530-538. PubMed ID: 31122493
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial.
    Lotery A; Sivaprasad S; O'Connell A; Harris RA; Culliford L; Ellis L; Cree A; Madhusudhan S; Behar-Cohen F; Chakravarthy U; Peto T; Rogers CA; Reeves BC;
    Lancet; 2020 Jan; 395(10220):294-303. PubMed ID: 31982075
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
    Saad F; Thiery-Vuillemin A; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Kang J; Burgents J; Gresty C; Degboe A; Clarke NW
    Lancet Oncol; 2022 Oct; 23(10):1297-1307. PubMed ID: 36063830
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial.
    Haal S; Guman MSS; Boerlage TCC; Acherman YIZ; de Brauw LM; Bruin S; de Castro SMM; van Hooft JE; van de Laar AWJM; Moes DE; Schouten M; Schouten R; van Soest EJ; van Veen RN; de Vries CEE; Fockens P; Dijkgraaf MGW; Gerdes VEA; Voermans RP
    Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):993-1001. PubMed ID: 34715031
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series.
    Bullock R; Cameron A
    Curr Med Res Opin; 2002; 18(5):258-64. PubMed ID: 12240787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.